BILL COMPUNICATIONS – Trademark Portfolio

Entity Type: 03

BILL COMPUNICATIONS holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MEDTRADE. The owner is based in NEW YORK, NY.

355 PARK AVENUE SOUTH

NEW YORK, NY 10010-178

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MEDTRADE
MEDTRADE
Registered 1993

Trademark Classifications

BILL COMPUNICATIONS's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does BILL COMPUNICATIONS have?

BILL COMPUNICATIONS has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does BILL COMPUNICATIONS file in?

BILL COMPUNICATIONS files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 41 (Education & Entertainment). Class 35 covers advertising; business management; business administration; office functions.

What are BILL COMPUNICATIONS's most well-known trademarks?

BILL COMPUNICATIONS's registered trademark portfolio includes well-known marks such as MEDTRADE. These are among 1 currently registered trademark in the portfolio.

What is BILL COMPUNICATIONS's trademark registration success rate?

BILL COMPUNICATIONS has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.